Efficacy parameter | Test group (MCT/LCT/FO-derived n-3 PUFAs) N = 15 | Control group (MCT/LCT) N = 18 |
---|---|---|
BMI (kg/m2) | ||
 Baseline | 21.9 ± 2.4 | 20.7 ± 2.4 |
 V1 (4 weeks HPN) | 22.8 ± 2.2 | 21.2 ± 2.5 |
 V2 (8 weeks HPN) | 23.2 ± 2.6 | 21.3 ± 2.4 |
Mean treatment difference (V2-BL) = 0.63 kg/m2, CI 95%: [− 0.07; 1.32], p = 0.0768, t-test | ||
Body weight (kg) | ||
 Baseline | 63.1 ± 13.0 | 62.9 ± 10.7 |
 V1 (4 weeks HPN) | 65.6 ± 12.9 | 64.4 ± 10.8 |
 V2 (8 weeks HPN) | 66.7 ± 13.9 | 64.8 ± 11.0 |
Mean treatment difference (V2-BL) = 1.70 kg, CI 95%: [− 0.44; 3.84], p = 0.1153, t-test | ||
Body cell mass (kg)* | ||
 Baseline | 24.5 ± 6.3 | 22.9 ± 4.5 |
 V1 (4 weeks HPN) | 25.0 ± 6.0 | 23.7 ± 4.7 |
 V2 (8 weeks HPN) | 25.4 ± 6.7 | 24.4 ± 5.4 |
Mean treatment difference (V2-BL) = − 0.01 kg, CI 95%: [− 1.33; 1.32], p = 0.9939, t-test |